Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
GAITHERSBURG, Md., April 27, 2017 -- OpGen, Inc. (NASDAQ:OPGN) today announced that Tina S. Nova, Ph.D. has been appointed to its Board of Directors.
Dr. Nova is a life science industry veteran with extensive experience building and leading novel genomics-based businesses. She currently serves as president and chief executive officer of Molecular Stethoscope, Inc., a newly formed molecular diagnostics company. Most recently, she was senior vice president and general manager of Illumina's oncology business unit. From 2000 to 2014, Dr. Nova was a co-founder and director, president and chief executive officer of Genoptix Medical Laboratory, which was purchased by Novartis Pharmaceuticals Corporation for nearly $0.5 billion in 2011. She has also held senior positions with Nanogen, Inc., Ligand Pharmaceuticals, Inc. and Hybritech, Inc. Dr. Nova currently serves on the board of directors for Arena Pharmaceuticals and Veracyte and is vice chairman of the board of directors for the newly formed Rady Pediatric Genomics and Systems Medicine Institute, which is part of Rady Children's Hospital-San Diego. Dr. Nova holds a B.S. degree in Biological Sciences from the University of California, Irvine where she graduated with honors and a Ph.D. in Biochemistry from the University of California, Riverside.
“We are pleased to have Dr. Nova, a seasoned industry expert with a portfolio of high caliber successes, join the OpGen Board,” said Evan Jones, Chairman and CEO of OpGen. “Dr. Nova’s insights and experience from having built and advised successful molecular diagnostics companies will be invaluable as we continue to advance the development of our Acuitas Rapid Test and Acuitas Lighthouse Knowledgebase to combat the rise of multidrug-resistant organisms in our hospitals and health systems.”
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
Contact: OpGen Contact: Michael Farmer Director, Marketing 240-813-1284 [email protected] [email protected] Investor and Media Contact: MacDougall Biomedical Communications Cammy Duong 781-591-3443 [email protected]
